|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
25,230,000 |
Market
Cap: |
99.91(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.99 - $14.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,735 |
21,833 |
25,311 |
129,609 |
Total Sell Value |
$18,442 |
$258,319 |
$292,764 |
$349,328 |
Total People Sold |
4 |
4 |
4 |
4 |
Total Sell Transactions |
9 |
20 |
37 |
60 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stuglik Brian M |
Chief Executive Officer |
|
2022-01-03 |
4 |
S |
$2.05 |
$53,368 |
D/D |
(26,033) |
1,142,666 |
|
49% |
|
Paterson Dan |
President and COO |
|
2022-01-03 |
4 |
S |
$2.05 |
$48,245 |
D/D |
(23,534) |
480,751 |
|
49% |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2022-01-03 |
4 |
S |
$2.05 |
$40,205 |
D/D |
(19,612) |
559,289 |
|
49% |
|
Stuglik Brian M |
Chief Executive Officer |
|
2021-12-20 |
4 |
S |
$2.27 |
$31,058 |
D/D |
(13,682) |
1,168,699 |
|
36% |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2021-12-20 |
4 |
S |
$2.27 |
$12,478 |
D/D |
(5,497) |
578,901 |
|
36% |
|
Paterson Dan |
President and COO |
|
2021-12-20 |
4 |
S |
$2.27 |
$24,956 |
D/D |
(10,994) |
504,285 |
|
36% |
|
Paterson Dan |
President and COO |
|
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
181,500 |
515,279 |
|
- |
|
Stuglik Brian M |
Chief Executive Officer |
|
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
363,000 |
1,182,381 |
|
- |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
148,500 |
584,398 |
|
- |
|
Stuglik Brian M |
Chief Executive Officer |
|
2021-11-01 |
4 |
D |
$2.59 |
$15,123 |
D/D |
(5,839) |
819,381 |
|
- |
|
Paterson Dan |
President and COO |
|
2021-08-12 |
4 |
D |
$2.87 |
$144,200 |
D/D |
(50,244) |
333,779 |
|
- |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2021-08-12 |
4 |
D |
$2.87 |
$130,094 |
D/D |
(45,329) |
435,898 |
|
- |
|
Stuglik Brian M |
Chief Executive Officer |
|
2021-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
191,828 |
1,186,185 |
|
- |
|
Neumann Frank |
Chief Medical Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
67,925 |
571,635 |
|
- |
|
Stuglik Brian M |
Chief Executive Officer |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
203,776 |
994,357 |
|
- |
|
Paterson Dan |
President and COO |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
135,851 |
555,816 |
|
- |
|
Barberich Timothy J |
Director |
|
2020-12-04 |
4 |
B |
$2.17 |
$108,500 |
D/D |
50,000 |
218,000 |
2.39 |
22% |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2020-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
290,210 |
503,710 |
|
- |
|
Stuglik Brian M |
Chief Executive Officer |
|
2020-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
419,581 |
790,581 |
|
- |
|
Paterson Dan |
President and COO |
|
2020-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
321,679 |
419,965 |
|
- |
|
Shah Rajeev M. |
10% Owner |
|
2020-06-25 |
4 |
S |
$1.91 |
$2,219,941 |
I/I |
(1,161,300) |
16,142,051 |
|
32% |
|
Shah Rajeev M. |
10% Owner |
|
2020-04-27 |
4 |
S |
$2.31 |
$3,002,099 |
I/I |
(1,301,300) |
17,303,351 |
|
45% |
|
Gagnon Robert E. |
Chief Financial Officer |
|
2020-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
213,500 |
|
- |
|
Paterson Dan |
President and COO |
|
2020-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
98,286 |
|
- |
|
168 Records found
|
|
Page 4 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|